基于能谱CT的椎体羟基磷灰石浓度对肝硬化患者骨密度评估的诊断效能:评估静脉注射对比剂后平扫、动脉期和门静脉期的表现
研究纳入172例肝硬化患者,比较腹部能谱CT平扫、动脉期和门静脉期椎体羟基磷灰石浓度评估骨密度的诊断效能,以双能X线吸收法T值为参考标准。三个期相羟基磷灰石值差异有统计学意义,各期相诊断低骨量的曲线下面积均大于0.9;门静脉期诊断效能较平扫显著降低。
要点
- 肝硬化患者能谱CT椎体羟基磷灰石浓度在各期相均对低骨量有高诊断效能,曲线下面积均大于0.9。
- 动脉期与平扫诊断低骨量的效能差异无统计学意义(P=0.055)。
- 门静脉期诊断低骨量的效能较平扫显著降低(P=0.012),需上调阈值以维持高效能。
核心结论
- 与平扫相比,动脉期和门静脉期椎体羟基磷灰石浓度升高;在对比增强期相上调阈值可能维持对低骨量的高检出效能。
研究设计与样本
- 研究纳入172例肝硬化患者(平均年龄63.78±7.20岁,范围51-82岁),行腹部能谱CT平扫、动脉期和门静脉期扫描,以双能X线吸收法T值为参考标准。
诊断标准与关键数值
- 以双能X线吸收法T值为参考标准,各期相羟基磷灰石浓度诊断低骨量(骨质疏松或骨量减少)的曲线下面积均大于0.9;动脉期与平扫诊断低骨量的差异无统计学意义(P=0.055),门静脉期诊断效能较平扫显著降低(P=0.012)。
临床应用与阅片要点
- 在对比增强期相(动脉期和门静脉期)解读椎体羟基磷灰石浓度时,可上调阈值以维持对低骨量的高检出效能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To access the impact of intravenous contrast on the diagnostic efficacy of abdominal spectral CT-based vertebral hydroxyapatite (HAP) concentration measurement for bone mineral density (BMD) assessment in menopausal women, women undergoing menopausal transition, and men older than 50 years with liver cirrhosis.
METHODS: One hundred and seventy-two patients (mean age, 63.78 ± 7.20 years; range, 51-82 years) with liver cirrhosis enrolled in the study. These individuals underwent comprehensive abdominal spectral abdominal spectral CT scans, which included both unenhanced and contrast-enhanced arterial phase (AP) and portal venous phase (VP). Vertebral HAP concentration was quantified in the medullary compartment of vertebral body (L1-L3) using HAP-based material decomposition images. The receiver operating characteristic (ROC) curves were adapted to investigate the diagnostic efficacy of using unenhanced, AP and VP HAP concentrations for evaluating BMD validated by T-scores on dual-energy X-ray absorptiometry.
RESULTS: HAP values were significantly different among the 3 scan phases (all P < .05). By adjusting thresholds, high accuracies were obtained for detecting low bone mass (osteoporosis or osteopenia) with HAP measurements in all scan phases (all areas-under-ROC > 0.9). The data did not reveal a statistically significant disparity between the unenhanced and AP (P = .055) to detect low bone mass. The efficacies for detecting low bone mass had statistically significant reduction with HAP concentrations in VP (P = .012).
CONCLUSIONS: Vertebral HAP concentrations increased in AP and VP compared to unenhanced phase.
ADVANCES IN KNOWLEDGE: Adjusting thresholds higher in contrast-enhanced phases may maintain high detection efficacies for low bone mass.
引用
- Cheng X, Ma Q, Hou X, et al. Diagnostic ability of spectral CT-based vertebral hydroxyapatite concentration for bone mineral density assessment in patients with liver cirrhosis: evaluating in unenhanced, arterial, and portal venous phase after intravenous contrast administration. Br J Radiol. 2026. PMID: 41081609. doi:10.1093/bjr/tqaf250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。